Clinical Pharmacokinetics

, Volume 41, Issue 11, pp 853–876 | Cite as

Comprehensive Survey of the Relationship Between Serum Concentration and Therapeutic Effect of Amitriptyline in Depression

Review Articles Target Concentration Intervention

Abstract

The relationship between serum concentration (Cs) of amitriptyline and its therapeutic effect in depression has been investigated frequently over the last 3 decades; however, the results were controversial and no consensus was reached. Therefore, we have performed a comprehensive survey and meta-analysis of the subject. All relevant literature was included, and the design of studies on the serum concentration-therapeutic effect relationship (SCTER) of amitriptyline was evaluated. Pooled original data from SCTER studies with adequate design were analysed by various statistical methods: regression analysis of therapeutic effect and Cs; comparison of the mean therapeutic effect in various ranges of Cs; dichotomisation of outcome and analysis according to sensitivity of receiver operation curves; frequency of responders and nonresponders in ranges determined by points of sensitivity; analysis of the distribution of Cs in responders and nonresponders; logistic regression of responders and nonresponders with Cs and other independent variables; calculation of effect size (g) and mean effect size (gm).

Forty-five SCTER studies of amitriptyline were identified, and 27 studies met the minimum criteria of adequate study design. Inadequate study design predicted the finding of no SCTER. Analysis of the pooled data from studies with adequate design confirmed a therapeutic window of the sum of Cs of amitriptyline and its active metabolite nortriptyline of about 80 to 200 µg/L. A moderate and significant positive gm (0.538, 95% confidence interval 0.167 to 0.909) was calculated for treatment with Cs within the therapeutic window in comparison with treatment with Cs outside the therapeutic window (19 studies with adequate design and original data available, n = 583).

In conclusion, the evidence for a biphasic SCTER of amitriptyline in depression is considerably improved, and the results may help to find a consensus in the future. However, the clinical benefit of therapeutic drug monitoring of amitriptyline can only be demonstrated in a controlled and randomised study. Furthermore, the results provide further evidence that antidepressants at optimum Cs are superior to placebo in the treatment of depression.

References

  1. 1.
    Asberg M, Cronholm B, Sjöqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 1971; 4: 331–4CrossRefGoogle Scholar
  2. 2.
    Burrows GD, Davies B, Scoggins BA. Plasma concentrations of nortriptyline and clinical response in depressive illness. Lancet 1972; II: 619–23CrossRefGoogle Scholar
  3. 3.
    Orsulak PJ. Therapeutic drug monitoring of antidepressants: guidelines updated. Ther Drug Monit 1989; 11: 497–507PubMedCrossRefGoogle Scholar
  4. 4.
    Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring: principles and practice. Psychopharmacology 1993; 16: 611–41Google Scholar
  5. 5.
    Balant-Gorgia EA, Balant LP. Therapeutic drug monitoring: relevance during the drug treatment of psychiatric disorders. CNS Drugs 1995; 3(6): 432–53CrossRefGoogle Scholar
  6. 6.
    Braithwaite R, Goulding T, Theano G, et al. Plasma concentration of amitriptyline and clinical response. Lancet 1972; II: 1297–300CrossRefGoogle Scholar
  7. 7.
    Coppen A, Ghose K, Montgomery S, et al. Amitriptyline plasma concentration and clinical effect. Lancet 1978; 14: 63–6CrossRefGoogle Scholar
  8. 8.
    Glassman AH, Schildkraut JJ, Orsulak PJ, et al. Tricyclic anti-depressants, blood level measurements and clinical outcome: an APA task force report. Am J Psychiatry 1985; 142: 155–62Google Scholar
  9. 9.
    Kuss HJ, Jungkunz G, Holsbör F. Amitriptyline: looking through the therapeutic window. Lancet 1984; I: 464–5CrossRefGoogle Scholar
  10. 10.
    Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 1987; 13: 381–92PubMedCrossRefGoogle Scholar
  11. 11.
    Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230–40PubMedCrossRefGoogle Scholar
  12. 12.
    Grohmann R, Rüther E, Engel RR, et al. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatria 1999; 32: 21–8CrossRefGoogle Scholar
  13. 13.
    Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D, editors. Arzneiverordnungsreport 1998. Berlin: Springer, 1998: 455–78Google Scholar
  14. 14.
    Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Br J Psychiatry 2000; 177: 292–302PubMedCrossRefGoogle Scholar
  15. 15.
    Barbui C, Hotopf M. Amitriptyline vs the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001; 178: 129–44PubMedCrossRefGoogle Scholar
  16. 16.
    Ulrich S, Wurthmann C, Brosz M, et al. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia: a review. Clin Pharmacokinet 1998; 34: 227–63PubMedCrossRefGoogle Scholar
  17. 17.
    Quitkin FM, Rabkin JG, Gerald J, et al. Validity of clinical trials of antidepressants. Am J Psychiatry 2000; 157: 327–37PubMedCrossRefGoogle Scholar
  18. 18.
    Medawar C. The antidepressant web. Int J Risk Saf Med 1997; 10: 75–126Google Scholar
  19. 19.
    Medical Research Council Clinical Psychiatry Committee. Clinical trial of the treatment of depressive illness. BMJ 1965; 1: 881–6CrossRefGoogle Scholar
  20. 20.
    Baumann P, Jonzier-Perey M, Koeb L, et al. Amitriptyline pharmacokinetics and clinical response: metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986; 1: 102–12PubMedCrossRefGoogle Scholar
  21. 21.
    Breyer-Pfaff U, Gaertner HJ, Giedke H. Plasma levels, psychophysiological variables, and clinical response to amitriptyline. Psychiatr Res 1982; 6: 223–34CrossRefGoogle Scholar
  22. 22.
    Breyer-Pfaff U, Gaertner HJ, Kreuter F, et al. Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology 1982; 76: 240–4PubMedCrossRefGoogle Scholar
  23. 23.
    Breyer-Pfaff U, Giedke H, Gaertner HJ, et al. Validation of a therapeutic plasma level range in amitriptyline treatment of depression. J Clin Psychopharmacol 1989; 9: 116–21PubMedCrossRefGoogle Scholar
  24. 24.
    Burch JE, Ahmed O, Hullin RP, et al. Antidepressive effect of amitriptyline treatment with plasma drug levels controlled within three different ranges. Psychopharmacology 1988; 94: 197–205PubMedCrossRefGoogle Scholar
  25. 25.
    Coppen A, Ghose K, Jorgensen A. Pharmacokinetics and pharmacodynamics of amitriptyline in depression. Prog Neuropsychopharmacol 1979; 3: 191–9PubMedCrossRefGoogle Scholar
  26. 26.
    Click MA, Zisook S. Amoxapine and amitriptyline: serum levels and clinical response in patients with primary unipolar depression. J Clin Psychiaty 1982; 43: 369–71Google Scholar
  27. 27.
    Cournoyer G, De Montigny C, Ouellette J, et al. A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol 1987; 7: 385–93PubMedCrossRefGoogle Scholar
  28. 28.
    Corona GL, Fenoglia L, Pinelli P, et al. Amitriptyline and nortriptyline plasma levels and therapeutic response in depressed women. Pharmacopsychiatria 1977; 10: 299–308CrossRefGoogle Scholar
  29. 29.
    Corona GL, Pinelli P, Zerbi F, et al. Amitriptyline, nortriptyline plasma levels and clinical response in women with affective disorders. Pharmacopsychiatria 1980; 13: 102–10CrossRefGoogle Scholar
  30. 30.
    Corona GL, Zerbi F, Pinelli P, et al. Amitriptyline and nortriptyline plasma levels monitoring: perspective in clinical practice. Commun Psychopharmacol 1980; 4: 309–16PubMedGoogle Scholar
  31. 31.
    Corona GL, Cucchi ML, Fratini P, et al. Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression. Psychopharmacology 1990; 100: 334–8PubMedCrossRefGoogle Scholar
  32. 32.
    Edelbroek PM, Zitman FG, Schreuder JN, et al. Amitriptyline metabolism in relation to antidepressant effect. Clin Pharmacol Ther 1984; 35: 467–73PubMedCrossRefGoogle Scholar
  33. 33.
    Galuszko P, Jakitowicz J, Landowski J, et al. Plasma amitriptyline levels and its therapeutic effect in endogenous depression. Psychiar Pol 1987; 21: 110–4Google Scholar
  34. 34.
    Garaj V, Frank V, Drimalova M, et al. Relation of plasma amitriptyline and nortriptyline levels to the therapeutic response in endogenous depression. Cesk Psychiatr 1986; 82: 307–12PubMedGoogle Scholar
  35. 35.
    Jakitowicz J. The amitriptyline plasma levels and therapeutic response in patients with affective illness. Psychiat Pol 1991; 25: 14–20Google Scholar
  36. 36.
    Jungkunz G, Kuß HJ. On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients. Pharmakopsychiatr 1980; 13: 111–6CrossRefGoogle Scholar
  37. 37.
    Kocsis JH, Hanin I, Bowden C, et al. Imipramine and amitriptyline plasma concentrations and clinical response in major depression. Br J Psychiatry 1986; 148: 52–7PubMedCrossRefGoogle Scholar
  38. 38.
    Kupfer DJ, Hanin I, Spiker D, et al. Amitriptyline plasma levels and clinical response in primary depression: II. Commun Psychopharmacol 1978; 2: 441–50PubMedGoogle Scholar
  39. 39.
    Leclerc P, Carrier G, Billon B, et al. Tricyclic antidepressant plasma levels monitoring in daily practice: the Sherbrooke experience [abstract]. Clin Biochem 1983; 16: 118Google Scholar
  40. 40.
    Lehmann LS, Bowden CL, Redmont FC, et al. Amitriptyline and nortriptyline response profiles in unipolar depressed patients. Psychopharmacology 1982; 77: 193–7PubMedCrossRefGoogle Scholar
  41. 41.
    Liisberg P, Mose H, Amdisen A, et al. A clinical trial comparing sustained release amitriptyline (Amitriptyline, retard) and conventional amitriptyline tablets (Amitriptylin) in endogenously depressed patients with simultaneous determination of serum levels of amitriptyline and nortriptyline. Acta Psychiatr Scand 1978; 57: 426–35PubMedCrossRefGoogle Scholar
  42. 42.
    Liu P. Relation of plasma levels and clinical response to amitriptyline in treating endogenous depression. Chin J Neurol Psychiatry 1988; 21: 263–6Google Scholar
  43. 43.
    Loudon JB, Tiplady B, Ashcroft GW, et al. Zimelidine and amitriptyline in the treatment of depressive illness in general practice. Acta Psychiatr Scand Suppl 1981; 290: 454–63PubMedCrossRefGoogle Scholar
  44. 44.
    Mendlewicz J, Linkowski P, Rees JA. A double-blind comparison of dothiepin and amitriptylin in patients with primary affective disorder: serum levels and clinical response. Br J Psychiatry 1980; 136: 154–60PubMedCrossRefGoogle Scholar
  45. 45.
    Miljkovic B, Pokrajac M, Timotijevic I, et al. Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients. Eur J Drug Metab Pharmacokinet 1996; 21: 251–5PubMedCrossRefGoogle Scholar
  46. 46.
    Monteleone P, Fabrazzo M. Blood levels of mianserin and amitriptyline and clinical response in aged depressed patients. Pharmacopsychiatry 1994; 27: 238–41PubMedCrossRefGoogle Scholar
  47. 47.
    Montgomery SA, McAuley R, Rani SJ, et al. Amitriptyline plasma concentrations and clinical response. BMJ 1979; 27: 230–1CrossRefGoogle Scholar
  48. 48.
    Montgomery SA, McAuley R, Montgomery DB, et al. Pharmacokinetics and efficacy of maprotiline and amitriptyline in endogenous depression: a double-blind controlled trial. Clin Ther 1980; 3: 292–310PubMedGoogle Scholar
  49. 49.
    Moyes IC, Ray RL, Moyes RB. Plasma levels and clinical improvement: a comparative study of clomipramine and amitriptyline in depression. Postgrad Med J 1980; 56 Suppl. 1: 127–9PubMedGoogle Scholar
  50. 50.
    Olig RM, Staton RD, Beatty WW, et al. Antidepressant treatment of children: clinical relapse is unrelated to tricyclic plasma concentrations. Percept Mot Skills 1985; 60: 879–89PubMedCrossRefGoogle Scholar
  51. 51.
    Pidrman V, Krpalek P. Levels of amitriptyline and its metabolism in the treatment of depression. Cesk Psychiatr 1991; 87: 209–18PubMedGoogle Scholar
  52. 52.
    Quednow B, Walter H, Genz A, et al. Amitriptyline levels and clinical effects. Agressologie 1981; 22: 15–8PubMedGoogle Scholar
  53. 53.
    Rao ML, Deister A, Laux G, et al. Low serum levels of tricyclic antidepressants in amitriptyline and doxepin treated inpatients with depressive syndromes are associated with non-response. Pharmacopsychiatria 1996; 29: 97–102CrossRefGoogle Scholar
  54. 54.
    Rickels K, Weise C, Case G, et al. Tricyclic plasma levels in depressed outpatients treated with amitriptyline. Psychopharmacology 1983; 80: 14–8PubMedCrossRefGoogle Scholar
  55. 55.
    Robinson DS, Cooper TB, Ravaris CL, et al. Plasma tricyclic drug levels in amitriptyline-treated depressed patients. Psychopharmacology 1979; 63: 223–31PubMedCrossRefGoogle Scholar
  56. 56.
    Robinson DS, Cooper TB, Howard D, et al. Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients. J Clin Psychopharmacol 1985; 5: 83–8PubMedGoogle Scholar
  57. 57.
    Rowan PR, Paykel ES, Marks V, et al. Serum levels and response to amitriptyline in depressed out-patients. Neuropsychobiology 1984; 12: 9–15PubMedCrossRefGoogle Scholar
  58. 58.
    Schnyder C, Baumann P, Jonzier-Perey M, et al. Use of amitriptyline in low dose in gerontopsychiatry. Schweiz Med Wochenschr 1985; 115: 1128–34PubMedGoogle Scholar
  59. 59.
    Shimoda K, Yasuda S, Morita S, et al. Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. Psychiatry Clin Neurosci 1997; 51: 35–41PubMedCrossRefGoogle Scholar
  60. 60.
    Ulrich S, Northoff G, Wurthmann C, et al. Serum levels of amitriptyline and therapeutic effect in non-delusional moderate to severely depressed in-patients: a therapeutic window relationship. Pharmacopsychiatria 2001; 34: 33–40CrossRefGoogle Scholar
  61. 61.
    Vandel S, Vandel B, Sandoz M, et al. Clinical response and plasma concentration of amitriptyline and its metabolite nor-triptyline. Eur J Clin Pharmacol 1978; 14: 185–90PubMedCrossRefGoogle Scholar
  62. 62.
    Gurney C, Roth M, Garside RF, et al. Studies in the classification of affective disorders. Br J Psychiatry 1972; 121: 162–6PubMedCrossRefGoogle Scholar
  63. 63.
    Vandel S, Vandel B, Allers G, et al. Interaction between Amitriptyline and phenothiazine in man: effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response. Psychopharmacology 1979; 65: 187–90PubMedCrossRefGoogle Scholar
  64. 64.
    Zhang X. Serum concentrations of amitriptyline and its metabolites and clinical effect in depressive patients. Chin J Neurol Psychiatry 1992; 25: 196–8Google Scholar
  65. 65.
    Ziegler VE, Clayton PJ, Biggs JT. A comparison study of amitriptyline and nortriptyline with plasma levels. Arch Gen Psychiatry 1977; 34: 607–12PubMedCrossRefGoogle Scholar
  66. 66.
    D’Agostino RB, Weintraub M. Meta-analysis: a method for synthesizing research. Clin Pharmacol Ther 1995; 58: 605–15PubMedCrossRefGoogle Scholar
  67. 67.
    Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452–4PubMedCrossRefGoogle Scholar
  68. 68.
    Ziegler VE, Meyer DA, Rosen SH, et al. Amitriptyline dosage schedule, sampling time and tricyclic plasma levels. Br J Psychiatry 1977; 131: 168–71PubMedCrossRefGoogle Scholar
  69. 69.
    Dawling S. Monitoring of tricyclic antidepressant therapy. Clin Biochem 1982; 15: 56–61PubMedCrossRefGoogle Scholar
  70. 70.
    Wallace JE, Hamilton HE, Goggin LK, et al. Determination of amitriptyline at nanogram levels in serum by electron capture gas-liquid chromatography. Anal Chem 1975; 47: 1516–9PubMedCrossRefGoogle Scholar
  71. 71.
    Mould GP, Stout G, Aherne GW, et al. Radioimmunoassay of amitriptyline and nortriptyline in body fluids. Ann Clin Biochem 1978; 15: 221–5PubMedGoogle Scholar
  72. 72.
    Rao ML, Staberock U, Baumann P, et al. Monitoring tricyclic antidepressant concentration in serum by FPIA compared with GC and HPLC. Clin Chem 1994; 40: 929–33PubMedGoogle Scholar
  73. 73.
    Davis JM, Wang Z. Power analysis for correlation of plasma level and clinical data. In: Gram LF, Balant LP, Meltzer HY, et al., editors. Clinical pharmacology in psychiatry. Berlin: Springer, 1993: 253–64CrossRefGoogle Scholar
  74. 74.
    Stolley PD, Strom BL. Sample size calculations for clinical pharmacological studies. Clin Pharmacol Ther 1986; 39: 489–90PubMedCrossRefGoogle Scholar
  75. 75.
    Preskorn SH. Factors affecting the biphasic concentration: effect relationships of tricyclic antidepressants. In: Dahl S, Usdin E, editors. Clinical pharmacology in psychiatry. London: McMillan, 1981: 297–306Google Scholar
  76. 76.
    Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991; 52 Suppl. 6: 23–33PubMedGoogle Scholar
  77. 77.
    Meador-Woodruff JH, Akil M, Wisner-Carlson R, et al. Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels. J Clin Psychopharmacol 1988; 8: 28–32PubMedCrossRefGoogle Scholar
  78. 78.
    Meador-Woodruff JH, Grunhaus L. Profound behavioral toxicity due to tricyclic antidepressants. J Nerv Ment Dis 1986; 174: 628–30PubMedCrossRefGoogle Scholar
  79. 79.
    Janicak PG, Javaid JI, Davis JM. Neuroleptic plasma levels: methodological issues, study design, and clinical applicability. In: Marder SR, Davis JM, Janicak PG, editors. Clinical use of neuroleptic plasma levels. Washington: Am Psych Press, 1993: 17–44Google Scholar
  80. 80.
    Teicher MH, Baldessarini RJ. Selection of neuroleptic dosage. Arch Gen Psychiatry 1985; 42: 636–7PubMedCrossRefGoogle Scholar
  81. 81.
    Hirschfeld RMA. Psychosocial predictors of outcome in depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the 4th generation of progress. New York: Raven, 1995: 1113–21Google Scholar
  82. 82.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12PubMedCrossRefGoogle Scholar
  83. 83.
    Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999; 174: 297–303PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Institute of Clinical PharmacologyUniversity HospitalMagdeburgGermany
  2. 2.Institute of Biometry and Medical InformaticsUniversity Hospital, Otto-von-Guericke UniversityMagdeburgGermany
  3. 3.Institute of Clinical PharmacologyUniversity Hospital MagdeburgMagdeburgGermany

Personalised recommendations